Science
Scientists Identify Critical Drug Target for 'Brain on Fire' Autoimmune Disease
Researchers have pinpointed a molecular weak spot in anti-NMDA receptor encephalitis, the devastating autoimmune condition known as 'Brain on Fire.' The discovery opens the door to targeted therapies for a disease that attacks memory and cognition, causing psychiatric symptoms, seizures, and death.
Key Takeaways
- Scientists identified how antibodies trigger NMDA receptor internalization in 'Brain on Fire' disease
- Discovery reveals specific molecular targets for new drugs
- Current treatments broadly suppress the immune system with significant side effects
- A targeted therapy could block the disease mechanism without compromising immunity
- The condition predominantly strikes young adults and children, often mimicking psychiatric illness
DE
DT Editorial AI··via sciencedaily.com